Lyndra Therapeutics Advances Leadership in Key Roles
Retrieved on:
Monday, September 20, 2021
Mental Health, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Food, Therapy, Food and Drug Administration, AIG, Ballinger, American International Group, Board of directors, FDA, H. Keith Moo-Young, Patient, Legacy Fighting Alliance in 2018, Peripheral nervous system, Thought disorder, Board, Bill, Medicine, Growth, Risperidone, Risk management, Leadership, Bill & Melinda Gates Foundation, NIH, Investment, Chief business officer, Schizophrenia, Pharmaceutical industry, Management
Ballinger has been a member of the Lyndra leadership team since 2016, and has played a leading role in building Lyndra as Chief Operations Officer and, previously, Vice President of Reimbursement and Strategic Alliances.
Key Points:
- Ballinger has been a member of the Lyndra leadership team since 2016, and has played a leading role in building Lyndra as Chief Operations Officer and, previously, Vice President of Reimbursement and Strategic Alliances.
- Jess is a builder, said Dr. Patricia Hurter, Chief Executive Officer of Lyndra Therapeutics.
- Over the past five years, she has been a key partner in getting Lyndra to where it is today: on the cusp of our first pivotal trial and building toward commercialization.
- Thats the kind of leadership we value at Lyndra, and Im thrilled to continue to partner with her as we move Lyndra forward.